Valuation Valneva SE London S.E.

Stocks

Market Closed - London S.E. 03:03:24 2026-05-14 EDT			5-day change	1st Jan Change
2.592 ^EUR	-38.30%		-10.72%	-30.05%

08-14	Pfizer and Valneva Se Announce European Medicines Agency Validation of Marketing Authorization Application for Lyme Disease Vaccine Candidate	CI
08-14	Pfizer Inc. and Valneva Se Enter Strategic Alliance for Co-Development of Lyme Disease Vaccine Candidate	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	2,574	861.1	655.1	351.1	642.3	562.5	-	-
Change	-	-66.55%	-23.93%	-46.4%	82.94%	-12.43%	-	-
Enterprise Value (EV) ¹	2,286	670.5	737.8	399.1	739.9	696.2	625	614.2
Change	-	-70.66%	10.04%	-45.9%	85.38%	-5.91%	-10.23%	-1.72%
P/E	-32.7x	-5.02x	-6.47x	-27x	-5.47x	-6.81x	10.7x	14.2x
PBR	15.1x	-	5.1x	1.94x	6.07x	10.5x	4.41x	3.25x
PEG	-	-0.1x	0.2x	0.3x	-0x	0.2x	-0x	-0.6x
Capitalization / Revenue	7.4x	2.38x	4.26x	2.07x	3.68x	3.73x	1.99x	2.26x
EV / Revenue	6.57x	1.86x	4.8x	2.35x	4.24x	4.61x	2.21x	2.47x
EV / EBITDA	-48.5x	-9.69x	-11.3x	12.1x	-12.5x	-20.7x	6.03x	11.4x
EV / EBIT	-37.2x	-5.91x	-8.99x	29.9x	-9.12x	-12x	8.09x	11.5x
EV / FCF	-140x	-2.44x	-3.4x	-4.92x	-12.9x	-14.8x	6.81x	80.5x
FCF Yield	-0.71%	-41%	-29.4%	-20.3%	-7.75%	-6.74%	14.7%	1.24%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-0.75	-1.24	-0.73	-0.08	-0.68	-0.4357	0.2762	0.2083
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	348.1	361.3	153.7	169.6	174.7	151	283.4	248.4
EBITDA ¹	-47.1	-69.2	-65.24	32.92	-59.42	-33.62	103.7	53.7
EBIT ¹	-61.4	-113.4	-82.09	13.33	-81.16	-57.79	77.25	53.6
Net income ¹	-73.4	-143.3	-101.4	-12.25	-115.2	-81.11	53.07	28.74
Net Debt ¹	-288.9	-190.6	82.74	48.04	97.6	133.7	62.48	51.7
Reference price ²	24.500	6.224	4.720	2.162	3.718	2.966	2.966	2.966
Nbr of stocks (in thousands)	105,078	138,355	138,788	162,397	172,759	189,647	-	-
Announcement Date	2/3/22	3/23/23	3/21/24	3/20/25	3/17/26	-	-	-

¹EUR in Million²EUR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
LONZA GROUP AG	34.4x	6.13x	18.24x	0.93%	51.22B
REVOLUTION MEDICINES, INC.	-21.71x	301.09x	-22.35x	-.--%	45.38B
IQVIA HOLDINGS INC.	32.97x	3.21x	13.87x	-.--%	42.15B
BEONE MEDICINES AG	48.36x	5.61x	30.68x	-.--%	41.97B
CELLTRION, INC.	29.48x	8.52x	21.54x	0.39%	31.95B
MEDPACE HOLDINGS, INC.	34.84x	5.71x	25.97x	-.--%	17.1B
EUROFINS SCIENTIFIC SE	24.28x	2.11x	9.12x	1.11%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	77.97x	4.1x	15.89x	-.--%	13.91B
Average	32.57x	42.06x	14.12x	0.3%	32.31B
Weighted average by Cap.	27.77x	57.29x	12.69x	0.3%